ROTE WILLIAM E.

SEC source: 0001698262-26-000005 · form4-09182026_010952.xml · derivative · entry 16

ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 57,500 shares

Expires 2031-01-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: The stock option is fully vested and exercisable.

SEC source: 0001698262-26-000005 · form4-09182026_010952.xml · derivative · entry 15

ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 55,000 shares

Expires 2030-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: The stock option is fully vested and exercisable.

SEC source: 0001698262-26-000005 · form4-09182026_010952.xml · derivative · entry 14

ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 350 shares

Expires 2029-05-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: The stock option is fully vested and exercisable.

SEC source: 0001698262-26-000005 · form4-09182026_010952.xml · nonDerivative · entry 11

ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 98,197

F2 · kind: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

F7 · price: The weighted average sale price for the transaction reported was $63.6126, and the range of prices were between $63.47 and $63.96. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

SEC source: 0001698262-26-000005 · form4-09182026_010952.xml · nonDerivative · entry 10

ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 145,943

F2 · kind: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

F6 · price: The weighted average sale price for the transaction reported was $63.1205, and the range of prices were between $62.47 and $63.4650. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

SEC source: 0001698262-26-000005 · form4-09182026_010952.xml · nonDerivative · entry 9

ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 211,047

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001698262-26-000005 · form4-09182026_010952.xml · nonDerivative · entry 8

ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 153,547

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001698262-26-000005 · form4-09182026_010952.xml · nonDerivative · entry 7

ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 98,547

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001698262-26-000005 · form4-09182026_010952.xml · derivative · entry 13

ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 350

Underlying: Common Stock · 39,650 shares

Expires 2029-05-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: The stock option is fully vested and exercisable.

SEC source: 0001698262-26-000005 · form4-09182026_010952.xml · derivative · entry 12

ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 39,000 shares

Expires 2028-05-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: The stock option is fully vested and exercisable.

SEC source: 0001698262-26-000005 · form4-09182026_010952.xml · nonDerivative · entry 6

ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 98,197

F2 · kind: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

SEC source: 0001698262-26-000005 · form4-09182026_010952.xml · nonDerivative · entry 5

ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 98,467

F2 · kind: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

F5 · price: The weighted average sale price for the transaction reported was $63.6508, and the range of prices were between $63.49 and $63.99. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided

SEC source: 0001698262-26-000005 · form4-09182026_010952.xml · nonDerivative · entry 4

ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 101,467

F2 · kind: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

F4 · price: The weighted average sale price for the transaction reported was $62.6552 and the range of prices were between $62.41 and $63.32. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

SEC source: 0001698262-26-000005 · form4-09182026_010952.xml · nonDerivative · entry 3

ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 130,488

F2 · kind: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

F3 · price: The weighted average sale price for the transaction reported was $61.994, and the range of prices were between $61.405 and $62.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

SEC source: 0001698262-26-000005 · form4-09182026_010952.xml · nonDerivative · entry 2

ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 194,395

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001698262-26-000005 · form4-09182026_010952.xml · nonDerivative · entry 1

ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 154,745

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 271 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 29, 2026.

SEC source: 0001698262-26-000004 · form4-05062026_080513.xml · nonDerivative · entry 2

ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 115,474

F2 · kind: This sale was made pursuant to a written plan adopted on May 29, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

SEC source: 0001698262-26-000004 · form4-05062026_080513.xml · derivative · entry 4

ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,250

Underlying: Common Stock · 4,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Issuer's common stock at target, subject to adjustment based on the achievement of applicable performance conditions.

F1 · kind: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion.

F1 · derivative.exercise_date: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion.

F1 · derivative.expiration_date: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion.

SEC source: 0001698262-26-000004 · form4-05062026_080513.xml · derivative · entry 3

ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,500

Underlying: Common Stock · 8,500 shares

Expires not disclosed

F3 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Issuer's common stock at target, subject to adjustment based on the achievement of applicable performance conditions.

F1 · kind: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion.

F1 · derivative.exercise_date: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion.

F1 · derivative.expiration_date: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion.

SEC source: 0001698262-26-000004 · form4-05062026_080513.xml · nonDerivative · entry 1

ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 118,237

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion.

SEC source: 0001698262-26-000003 · form4-04232026_040401.xml · nonDerivative · entry 1

ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 113,987

F1 · kind: This sale was made pursuant to a written plan adopted on May 29, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

SEC source: 0001698262-26-000002 · form4-04162026_010440.xml · nonDerivative · entry 1

ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 123,087

F1 · kind: On January 31, 2025, the reporting person was granted performance restricted stock units (PSUs) which PSUs vested on April 13, 2026 upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted approval of FILSPARI (sparsentan) in FSGS.

SEC source: 0001698262-26-000001 · form4-02032026_090205.xml · nonDerivative · entry 2

ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 109,087

F2 · kind: This sale was made pursuant to a written plan adopted on May 29, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001698262-26-000001 · form4-02032026_090205.xml · derivative · entry 3

ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 53,570

Underlying: Common Stock · 53,570 shares

Expires 2036-01-31

F3 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001698262-26-000001 · form4-02032026_090205.xml · nonDerivative · entry 1

ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 121,533

F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

SEC source: 0001698262-25-000005 · form4-12302025_021233.xml · derivative · entry 3

ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 60,000 shares

Expires 2027-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The stock option is fully vested and exercisable.

SEC source: 0001698262-25-000005 · form4-12302025_021233.xml · nonDerivative · entry 2

ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 101,443

F2 · kind: This sale was made pursuant to a written plan adopted on May 29, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on February 13, 2017, with an expiration date of February 13, 2027.

F3 · price: The weighted average sale price for the transaction reported was $40.103, and the range of prices were between $38.00 and $42.07. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

SEC source: 0001698262-25-000005 · form4-12302025_021233.xml · nonDerivative · entry 1

ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 161,443

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 607 shares of Common Stock that were acquired by the Reporting Person on May 30, 2025, and 595 shares of Common Stock that were acquired by the Reporting Person on November 28, 2025, pursuant to the Issuer's Employee Stock Purchase Plan.

SEC source: 0001415889-25-012056 · form4-05062025_010518.xml · nonDerivative · entry 2

ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 100,241

F3 · kind: This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

SEC source: 0001415889-25-012056 · form4-05062025_010518.xml · derivative · entry 3

ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,920

Underlying: Common Stock · 4,920 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the common stock of the Issuer.

F1 · kind: On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved.

F1 · derivative.exercise_date: On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved.

F1 · derivative.expiration_date: On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved.

SEC source: 0001415889-25-012056 · form4-05062025_010518.xml · nonDerivative · entry 1

ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,439

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved.

F2 · price: Each PSU represents a contingent right to receive one share of the common stock of the Issuer.

SEC source: 0001415889-25-003824 · form4-02132025_020257.xml · nonDerivative · entry 2

ROTE WILLIAM E. · CIK 0001698262 · SENIOR VICE PRESIDENT, R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 98,519

F3 · kind: This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of the PSUs.

SEC source: 0001415889-25-003824 · form4-02132025_020257.xml · derivative · entry 3

ROTE WILLIAM E. · CIK 0001698262 · SENIOR VICE PRESIDENT, R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the common stock of the Issuer.

F1 · kind: On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 8,000 shares of the Issuer's common stock, to vest upon the satisfaction of certain clinical/regulatory performance criteria. On February 10, 2025, the PSUs vested upon the Issuer's confirmation that the clinical/regulatory performance criteria had been satisfied, including confirming a path forward for submitting an sNDA for traditional approval of FILSPARI (sparsentan) in FSGS.

F2 · derivative.exercise_date: Each PSU represents a contingent right to receive one share of the common stock of the Issuer.

F2 · derivative.expiration_date: Each PSU represents a contingent right to receive one share of the common stock of the Issuer.

SEC source: 0001415889-25-003824 · form4-02132025_020257.xml · nonDerivative · entry 1

ROTE WILLIAM E. · CIK 0001698262 · SENIOR VICE PRESIDENT, R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,719

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 8,000 shares of the Issuer's common stock, to vest upon the satisfaction of certain clinical/regulatory performance criteria. On February 10, 2025, the PSUs vested upon the Issuer's confirmation that the clinical/regulatory performance criteria had been satisfied, including confirming a path forward for submitting an sNDA for traditional approval of FILSPARI (sparsentan) in FSGS.

F2 · price: Each PSU represents a contingent right to receive one share of the common stock of the Issuer.

SEC source: 0001415889-25-003067 · form4-02042025_080224.xml · nonDerivative · entry 2

ROTE WILLIAM E. · CIK 0001698262 · SENIOR VICE PRESIDENT, R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 95,719

F2 · kind: This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001415889-25-003067 · form4-02042025_080224.xml · derivative · entry 3

ROTE WILLIAM E. · CIK 0001698262 · SENIOR VICE PRESIDENT, R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 58,000

Underlying: Common Stock · 58,000 shares

Expires 2035-01-31

F3 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001415889-25-003067 · form4-02042025_080224.xml · nonDerivative · entry 1

ROTE WILLIAM E. · CIK 0001698262 · SENIOR VICE PRESIDENT, R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 104,670

F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

SEC source: 0001415889-25-002008 · form4-01242025_010159.xml · nonDerivative · entry 1

ROTE WILLIAM E. · CIK 0001698262 · SENIOR VICE PRESIDENT, R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 83,170

F1 · kind: This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

F2 · balance_after: Includes 1,152 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on November 29, 2024.

SEC source: 0001415889-24-023096 · form4-09092024_090913.xml · nonDerivative · entry 2

ROTE WILLIAM E. · CIK 0001698262 · SENIOR VICE PRESIDENT, R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 84,455

F3 · kind: This sale was made pursuant to a written plan adopted March 15, 2024 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

SEC source: 0001415889-24-023096 · form4-09092024_090913.xml · nonDerivative · entry 1

ROTE WILLIAM E. · CIK 0001698262 · SENIOR VICE PRESIDENT, R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 88,842

F1 · kind: On January 31, 2023, the reporting person was granted performance restricted stock units (PSUs) covering 6,750 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On September 5, 2024, the PSUs vested upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted full approval to FILSPARI (sparsentan) in IgA Nephropathy.

F2 · balance_after: Includes 1,372 shares of Common Stock that were acquired by the Reporting Person on May 31, 2024 pursuant to the Issuer's Employee Stock Purchase Plan.

SEC source: 0001415889-24-002284 · form4-02022024_040225.xml · nonDerivative · entry 3

ROTE WILLIAM E. · CIK 0001698262 · SENIOR VICE PRESIDENT, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,720

F3 · kind: This sale was made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001415889-24-002284 · form4-02022024_040225.xml · nonDerivative · entry 2

ROTE WILLIAM E. · CIK 0001698262 · SENIOR VICE PRESIDENT, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,310

F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

SEC source: 0001415889-24-002284 · form4-02022024_040225.xml · derivative · entry 4

ROTE WILLIAM E. · CIK 0001698262 · SENIOR VICE PRESIDENT, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2034-01-30

F4 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001415889-24-002284 · form4-02022024_040225.xml · nonDerivative · entry 1

ROTE WILLIAM E. · CIK 0001698262 · SENIOR VICE PRESIDENT, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,484

F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

SEC source: 0001415889-24-001800 · form4-01252024_040111.xml · nonDerivative · entry 1

ROTE WILLIAM E. · CIK 0001698262 · SENIOR VICE PRESIDENT, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,484

F1 · kind: This sale was made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

F2 · balance_after: Includes 1,373 shares of the Issuer's common stock acquired by the reporting person on November 30, 2023 pursuant to an employee stock purchase program.

SEC source: 0001209191-23-048257 · doc4.xml · nonDerivative · entry 2

ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,173

F3 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

SEC source: 0001209191-23-048257 · doc4.xml · nonDerivative · entry 1

ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,988

F1 · kind: On January 31, 2020, the reporting person was granted performance restricted stock units (PRSUs) covering 5,000 shares of the Issuer's common stock. On August 31, 2023, PRSUs vested upon the closing of the sale of the Company's bile acid portfolio following a modification approved by the Compensation Committee for a reduced number of shares to vest under PRSUs originally granted on January 31, 2020 that were to vest upon specified clinical or regulatory milestones related to the Company's bile acid portfolio.

F2 · balance_after: Includes 477 shares of the Issuer's common stock acquired by the reporting person on May 31, 2023 pursuant to an employee stock purchase program.

SEC source: 0001209191-23-029000 · doc4.xml · nonDerivative · entry 1

ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 59,211

F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan adopted by the Reporting Person on November 10, 2022 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-23-006432 · doc4.xml · nonDerivative · entry 2

ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,036

F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-23-006432 · doc4.xml · derivative · entry 4

ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,750

Underlying: Common Stock · 6,750 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

F4 · derivative.exercise_date: This grant will vest upon the achievement of a specified clinical/regulatory milestone, provided, however, if the vesting event occurs before the date that is 12 months after the date of grant, then the award will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 if the specified performance based milestone is not achieved by such date.

F4 · derivative.expiration_date: This grant will vest upon the achievement of a specified clinical/regulatory milestone, provided, however, if the vesting event occurs before the date that is 12 months after the date of grant, then the award will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 if the specified performance based milestone is not achieved by such date.